<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37218386</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2125</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Azathioprine-induced vanishing bile duct syndrome: The value of early thiopurine metabolism assessment.</ArticleTitle><Pagination><StartPage>2625</StartPage><EndPage>2630</EndPage><MedlinePgn>2625-2630</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.15797</ELocationID><Abstract><AbstractText>About 15% to 28% of patients treated with thiopurines experienced adverse drug reactions, such as haematological and hepatic toxicities. Some of these related to the polymorphic activity of the thiopurine S-methyltransferase (TPMT), the key detoxifying enzyme of thiopurine metabolism. We report here a case of thiopurine-induced ductopenia with a comprehensive pharmacological analysis on thiopurine metabolism. A 34-year-old woman, with a medical history of severe systemic lupus erythematosus with recent introduction of azathioprine therapy, presented with mild fluctuating transaminase blood levels consistent with a hepatocellular pattern, which evolved to a cholestatic pattern over the next weeks. A blood thiopurine metabolite assay revealed low 6-thioguanine nucleotides (6-TGN) level and a dramatically increased 6-methylmercaptopurine ribonucleotides (6-MMPN) level, together with an unfavourable [6-MMPN:6-TGN] metabolite ratio and a high TPMT activity. After a total of about 6&#xa0;months of thiopurine therapy, a transjugular liver biopsy revealed a ductopenia, and azathioprine discontinuation led to further clinical improvement. In line with previous reports from the literature, our case supports the fact that ductopenia is a rare adverse drug reaction of azathioprine. The mechanism of reaction is unknown but may involve high 6-MMPN blood level, due to unusual thiopurine metabolism (switched metabolism). Early therapeutic drug monitoring with measurement of 6-TGN and 6-MMPN blood levels may help physicians to identify patients at risk of similar duct injury.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chouchana</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9626-3571</Identifier><AffiliationInfo><Affiliation>Centre R&#xe9;gional de Pharmacovigilance, Service de Pharmacologie p&#xe9;rinatale, p&#xe9;diatrique et adulte, H&#xf4;pital Cochin, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terris</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-3571-7277</Identifier><AffiliationInfo><Affiliation>Service de Pathologie, H&#xf4;pital Cochin, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sogni</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3316-8785</Identifier><AffiliationInfo><Affiliation>Service d'h&#xe9;patologie, H&#xf4;pital Cochin, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treluyer</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2045-4742</Identifier><AffiliationInfo><Affiliation>Centre R&#xe9;gional de Pharmacovigilance, Service de Pharmacologie p&#xe9;rinatale, p&#xe9;diatrique et adulte, H&#xf4;pital Cochin, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costedoat-Chalumeau</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6031-574X</Identifier><AffiliationInfo><Affiliation>Centre de r&#xe9;f&#xe9;rence maladies auto-immunes et syst&#xe9;miques rares d'Ile de France, D&#xe9;partement de M&#xe9;decine interne, H&#xf4;pital Cochin, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cit&#xe9; (CRESS), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loriot</LastName><ForeName>Marie-Anne</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9102-2667</Identifier><AffiliationInfo><Affiliation>Unit&#xe9; de Pharmacog&#xe9;n&#xe9;tique, Service de Biochimie, H&#xf4;pital europ&#xe9;en Georges Pompidou, AP-HP.Centre, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1147, M&#xe9;decine Personnalis&#xe9;e Pharmacog&#xe9;nomique et Optimisation Th&#xe9;rapeutique (MEPPOT), Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>FTK8U1GZNX</RegistryNumber><NameOfSubstance UI="D013866">Thioguanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013873">Thionucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.-</RegistryNumber><NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>E7WED276I5</RegistryNumber><NameOfSubstance UI="D015122">Mercaptopurine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006150">Guanine Nucleotides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="Y">Azathioprine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013866" MajorTopicYN="N">Thioguanine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013873" MajorTopicYN="N">Thionucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008780" MajorTopicYN="N">Methyltransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001652" MajorTopicYN="N">Bile Ducts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015122" MajorTopicYN="N">Mercaptopurine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006150" MajorTopicYN="N">Guanine Nucleotides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ductopenia</Keyword><Keyword MajorTopicYN="N">hepatitis</Keyword><Keyword MajorTopicYN="N">pharmacogenomics</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">thiopurine</Keyword><Keyword MajorTopicYN="N">vanishing bile duct syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>3</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37218386</ArticleId><ArticleId IdType="doi">10.1111/bcp.15797</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gomoll&#xf3;n F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25. doi:10.1093/ecco-jcc/jjw168</Citation></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089</Citation></Reference><Reference><Citation>Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(1):15-36. doi:10.1111/j.1365-2036.2011.04905.x</Citation></Reference><Reference><Citation>Bj&#xf6;rnsson ES, Gu J, Kleiner DE, et al. Azathioprine and 6-mercaptopurine-induced liver injury: clinical features and outcomes. J Clin Gastroenterol. 2017;51(1):63-69. doi:10.1097/MCG.0000000000000568</Citation></Reference><Reference><Citation>Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118(4):705-713. doi:10.1016/S0016-5085(00)70140-5</Citation></Reference><Reference><Citation>Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-815. doi:10.1038/clpt.2011.58</Citation></Reference><Reference><Citation>Illamola SM, Echaabi AK, Mazeron C, Deshayes S, Loriot MA, Pallet N. Development and validation of a UPLC-UV method for the quantification of thiopurine methyltransferase enzyme activity in human erythrocytes. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1113:91-97. doi:10.1016/j.jchromb.2019.03.014</Citation></Reference><Reference><Citation>Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol. 1997;26(Suppl 1):31-35. doi:10.1016/S0168-8278(97)82330-6</Citation></Reference><Reference><Citation>Horsmans Y, Rahier J, Geubel AP. Reversible cholestasis with bile duct injury following azathioprine therapy. A case report. Liver. 1991;11(2):89-93. doi:10.1111/j.1600-0676.1991.tb00497.x</Citation></Reference><Reference><Citation>Sobesky R, Dusoleil A, Condat B, Bedossa P, Buffet C, Pelletier G. Azathioprine-induced destructive cholangitis. Am J Gastroenterol. 2001;96(2):616-617. doi:10.1111/j.1572-0241.2001.03582.x</Citation></Reference><Reference><Citation>Ashby K, Zhuang W, Gonz&#xe1;lez-Jimenez A, et al. Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. J Hepatol. 2021;75(2):333-341. doi:10.1016/j.jhep.2021.03.021</Citation></Reference><Reference><Citation>Chouchana L, Narjoz C, Roche D, et al. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Pharmacogenomics. 2014;15(6):745-757. doi:10.2217/pgs.14.32</Citation></Reference><Reference><Citation>Yan L, Zhang S, Eiff B, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther. 2000;68(2):210-219. doi:10.1067/mcp.2000.108674</Citation></Reference><Reference><Citation>Chouchana L, Roche D, Jian R, Beaune P, Loriot MA. Poor response to thiopurine in inflammatory bowel disease: how to overcome therapeutic resistance? Clin Chem. 2013;59(7):1023-1026. doi:10.1373/clinchem.2012.195750</Citation></Reference><Reference><Citation>van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther. 2012;35(10):1181-1189. doi:10.1111/j.1365-2036.2012.05084.x</Citation></Reference><Reference><Citation>Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5(2):209-214. doi:10.1016/j.cgh.2006.11.020</Citation></Reference><Reference><Citation>Alexander SPH, Fabbro D, Kelly E, et al. The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. Br J Pharmacol. 2019;176(S1):S297-S396. doi:10.1111/bph.14752</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>